Effectiveness

3TC (lamivudine, Epivir) is able to reduce HIV viral load and increase CD4 cell counts in the majority of people when taken in combination with at least two other antiretroviral drugs.1 It is effective against HIV-1 and HIV-2 and some evidence indicates that 3TC can penetrate the central nervous system where it is active against HIV.

3TC is given in combination, usually with a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor and at least one other nucleoside or nucleotide reverse transcriptase inhibitor, particularly AZT (zidovudine, Retrovir) or abacavir (Ziagen). 3TC was first licensed before protease inhibitors and NNRTIs were developed. Its licence was granted after clinical studies showed that it reduced disease progression, AIDS, and death by 66% when added to AZT monotherapy in both AZT-experienced and AZT-naive patients.2 3 4 5

EPIV HBV oral solution and tablets contain a sub-therapeutic dose of 3TC for treating HIV infection. Unless a HIV/HBV co-infected child requires a 3TC 100mg dose for treating HIV, these drugs are not interchangeable.

 

 

References

  1. Maggiolo F et al. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antivir Ther 6: 249-253, 2001
  2. Eron JJ et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 333: 1662-1669, 1995
  3. Kuritzkes DR et al. Drug resistance and virologic response in NUCA 3001, a randomised trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 10: 975-981, 1996
  4. Katlama C et al. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European Working Group. JAMA 276: 118-125, 1996
  5. Staszewski S et al. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA 276: 111-117, 1996
This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.